Impact of HCV protease-inhibitor-based triple therapy for chronic HCV genotype 1 infection

Antiviral Therapy

Volumn 16, Issue 8, 2011, Pages 1187-1201

  Ferenci, Peter ^a   Reddy, K Rajender ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOCEPREVIR; CYCLOSPORIN; ESCITALOPRAM; ORAL CONTRACEPTIVE AGENT; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PLACEBO; RIBAVIRIN; TACROLIMUS; TELAPREVIR;

ANEMIA; ANORECTAL DISEASE; COMBINATION CHEMOTHERAPY; DIARRHEA; DRESS SYNDROME; DRUG EFFICACY; DRUG INHIBITION; DRUG RESPONSE; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSGEUSIA; EOSINOPHILIA; GENETIC POLYMORPHISM; GENOTYPE; HEPATITIS C; HUMAN; IL28B GENE; MUTATOR GENE; NAUSEA; PRIORITY JOURNAL; PRURITUS; RASH; REVIEW; STEVENS JOHNSON SYNDROME; TREATMENT DURATION; TREATMENT OUTCOME; VIRUS RESISTANCE;

ANTIVIRAL AGENTS; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; OLIGOPEPTIDES; POLYETHYLENE GLYCOLS; PROLINE; PROTEASE INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOMBINANT PROTEINS; RIBAVIRIN; TREATMENT OUTCOME; VIRAL LOAD;

EID: 83455163791     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1934     Document Type: Review

References (55)

1. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49:1335-1374.
2. Reiberger T, Rutter K, Ferlitsch A, et al. Portal pressure predicts outcome and safety of antiviral therapy in cirrhotic patients with hepatitis C virus infection. Clin Gastroenterol Hepatol 2011; 9:602-608.e1.
3. Pawlotsky JM. Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus. Hepatology 2011; 53:1742-1751.
4. Halfon P, Locarnini S. Hepatitis C virus resistance to protease inhibitors. J Hepatol 2011; 55:192-206.
5. Pawlotsky JM. The results of Phase III clinical trials with telaprevir and boceprevir presented at the Liver Meeting 2010: a new standard of care for hepatitis C virus genotype 1 infection, but with issues still pending. Gastroenterology 2011; 140:746-754.
6. Hézode C, Forestier N, Dusheiko G, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009; 360:1839-1850.
7. Gane EJ, Roberts SK, Stedman CA, et al. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 2010; 376:1467-1475.
8. Lok A, Gardiner D, Lawitz E, et al. Combination therapy with BMS-790052 and BMS-650032 alone or with PEGIFN/RBV results in undetectable HCV RNA through 12 weeks of therapy in HCV genotype 1 null responders. Hepatology 2010; 52 Suppl 1:877A.
9. Zeuzem S, Buggisch P, Agarwal K, et al. Dual, triple, and quadruple combination treatment with a protease inhibitor (GS-9256) and a polymerase inhibitor (GS-9190) alone and in combination with ribavirin (RBV) or PEGIFN/RBV for up to 28 days in treatment naive genotype 1 HCV subjects. Hepatology 2010; 52 Suppl 1:400A.
10. Stepanova M, Kanwal F, El-Serag HB, Younossi ZM. Insurance status and treatment candidacy of hepatitis C patients: analysis of population-based data from the United States. Hepatology 2011; 53:737-745.
11. Beinhardt S, Staettermayer A, Rutter K, et al. Treatment of chronic hepatitis C genotype 1 patients at an academic center in Europe involved in prospective controlled trials - is there a selection bias? Hepatology 2011; doi: 10.1002/hep.24671
12. Dai CY, Yeh ML, Huang JF, Chuang WL, Yu ML. Insurance status and treatment candidacy of patients with hepatitis C: Taiwanese patients are luckier. Hepatology 2011; 53:1399.
13. Poordad F, McCone J, Jr., Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364:1195-1206.
14. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364:2405-2416.
15. Sherman KE, Flamm SL, Afdhal NH, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011; 365:1014-1024.
16. Kwo PY, Lawitz EJ, McCone J, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre Phase 2 trial. Lancet 2010; 376:705-716.
17. Marcellin P, Forns X, Goeser T, et al. Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C. Gastroenterology 2011; 140:459-468.e1.
18. Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364:1207-1217.
19. Flamm S, Lawitz E, Jacobson I, et al. High sustained virologic response (SVR) among genotype 1 previous non-responders and relapsers to peginterferon/ribavirin when re-treated with boceprevir (BOC) plus peginterferon alfa-2a/ribavirin. 46th Annual Meeting of the European Association for the Study of the Liver. 30 March - 3 April 2011, Berlin, Germany. Abstract 1366.
20. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364:2417-2428.
21. Arora S, Thornton K, Murata G, et al. Outcomes of treatment for hepatitis C virus infection by primary care providers. N Engl J Med 2011; 364:2199-2207.
22. Ferenci P, Fried MW, Shiffman ML, et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol 2005; 43:425-433. (Pubitemid 41111423)
23. Jensen DM, Morgan TR, Marcellin P, et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology 2006; 43:954-960. (Pubitemid 43724620)
24. Zeuzem S, Buti M, Ferenci P, et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 2006; 44:97-103. (Pubitemid 41772522)
25. Fried MW, Hadziyannis SJ, Shiffman ML, Messinger D, Zeuzem S. Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection. J Hepatol 2011; 55:69-75.
26. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461:399-401.
27. Victrelis prescribing information. Package insert 2011. Schering Corporation a subsidiary of Merck and Co., Whitehouse Station, NJ, USA.
28. Incivek prescribing information. Package insert 2011. Vertex pharmaceuticals Inc., Cambridge, MA, USA.
29. Thompson AJ, Muir AJ, Sulkowski MS, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010; 139:120-129.e18.
30. Aerssens J, Fanning G, Scholliers A, et al. Impact of IL28B genotype and pre-treatment serum IP-10 in treatment-naive genotype 1 HCV patients treated with TMC435 in combination with peginterferon alpha-2a and ribavirin in the PILLAR study. J Hepatol 2011; 54 Suppl 1:S5.
31. Sulkowski M, Reddy R, Afdhal N, et al. Anemia had no effect on efficacy outcomes in treatment-naive patients who received telaprevir-based regimens in the ADVANCE and ILLUMINATE phase 3 studies. 46th Annual Meeting of the European Association for the Study of the Liver. March 30-April 3, 2011 Berlin, Germany. Abstract 477.
32. Sulkowski MS, Poordad F, Manns MP, et al. Anemia during treatment with peginterferon alfa-2b/ribavirin with or without boceprevir is associated with higher SVR rates: analysis of previously untreated and previous-treatment- failure patients. J Hepatol 2011; 54 Suppl 1:S194.
33. Garg V, Van HR, Lee JE, Alves K, Nadkarni P, Luo X. Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology 2011; 54:20-27.
34. Lee JE, Van HR, Alves K, Smith F, Garg V. Effect of the hepatitis C virus protease inhibitor telaprevir on the pharmacokinetics of amlodipine and atorvastatin. Antimicrob Agents Chemother 2011; doi: 10.1128/AAC.00653-11
35. ClinicalTrials.gov. A study of danoprevir/ritonavir and Copegus with RO5024048 and/or Pegasys in patients with chronic hepatitis C. Clinical trials.gov NCT01331850. (Updated 19 July 2011. Accessed 14 June 2011.) Available from http://clinicaltrials.gov/ct2/show/NCT01331850?term=danoprevir&rank=1
36. Kuntzen T, Timm J, Berical A, et al. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients. Hepatology 2008; 48:1769-1778.
37. Gaudieri S, Rauch A, Pfafferott K, et al. Hepatitis C virus drug resistance and immune-driven adaptations: relevance to new antiviral therapy. Hepatology 2009; 49:1069-1082.
38. Chevaliez S, Rodriguez C, Soulier A, Ahmed-Belkacem A, Hézode C, Pawlotsky J-M. Molecular characterization of HCV resistance to telaprevir by means of ultra-deep pyrosequencing: preexisting resistant variants and dynamics of resistant populations. J Hepatol 2011; 54 Suppl 1:S30.
39. Rong L, Dahari H, Ribeiro RM, Perelson AS. Rapid emergence of protease inhibitor resistance in hepatitis C virus. Sci Transl Med 2010; 2:30ra32.
40. Sarrazin C, Kieffer TL, Bartels D, et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 2007; 132:1767-1777. (Pubitemid 46677938)
41. McCown MF, Rajyaguru S, Kular S, Cammack N, Najera I. GT-1a or GT-1b subtype-specific resistance profiles for hepatitis C virus inhibitors telaprevir and HCV-796. Antimicrob Agents Chemother 2009; 53:2129-2132.
42. Zeuzem S, Sulkowski M, Zoulim F, et al. Long-term follow-up of patients with chronic hepatitis C treated with telaprevir in combination with peginterferon alfa-2a and ribavirin: interim analysis of the EXTEND study. Hepatology 2010; 52 Suppl 1:436A.
43. Barnard R, Howe J, Graham D, et al. Durability of response and rate of reemergence of wild type at BOC resistance-associated variant loci in genotype-1a and -1b patients: interim analysis of long-term follow-up of patients treated with BOC+pegIFN/RBV. 18th Conference on Retroviruses and Opportunistic Infections. 27 February-2 March 2011, Boston, MA, USA. Abstract 117.
44. Buti M, Lurie Y, Zakharova NG, et al. Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virologic response. Hepatology 2010; 52:1201-1207.
45. Bronowicki JP, Ouzan D, Asselah T, et al. Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin. Gastroenterology 2006; 131:1040-1048. (Pubitemid 44515099)
46. Berg T, von Wagner M, Nasser S, et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 2006; 130:1086-1097.
47. Sánchez-Tapias JM, Diago M, Escartin P, et al. Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology 2006; 131:451-460. (Pubitemid 44142452)
48. McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009; 361:580-593.
49. Ferenci P, Laferl H, Scherzer TM, et al. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. Gastroenterology 2008; 135:451-458.
50. Mangia A, Minerva N, Bacca D, et al. Individualized treatment duration for hepatitis C genotype 1 patients: a randomized controlled trial. Hepatology 2008; 47:43-50. (Pubitemid 351171040)
51. Yu ML, Dai CY, Huang JF, et al. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial. Hepatology 2008; 47:1884-1893.
52. Liu CH, Liu CJ, Lin CL, et al. Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial. Clin Infect Dis 2008; 47:1260-1269.
53. Sarrazin C, Schwendy S, Moller B, et al. Improved responses to pegylated interferon alfa-2b and ribavirin by individualizing treatment for 24-72 weeks. Gastroenterology 2011; doi: 10.1053/j.gastro.2011.07.019
54. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-982.
55. Hadziyannis SJ, Sette H, Jr., Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140:346-355.